Virus NAT for HIV, HBV, and HCV in Post-Mortal Blood Specimens over 48 h after Death of Infected Patients – First Results

Objective: According to EU regulations (EU directive 2006/17/EC), blood specimens for virologic testing in the context of post-mortal tissue donation must be taken not later than 24 h post mortem. Methods: To verify validity of NAT in blood specimens collected later, viral nucleic acid concentrations were monitored in blood samples of deceased persons infected with HIV (n = 7), HBV (n = 5), and HCV (n = 17) taken upon admission and at 12 h, 24 h, 36 h and 48 h post mortem. HIV and HCV RNA were quantified using Cobas TaqMan (Roche), HBV DNA was measured by in-house PCR. Results: A more than 10-fold decrease of viral load in samples taken 36 h or 48 h post mortem was seen in one HIV-infected patient only. For all other patients tested the decrease of viral load in 36hour or 48-hour post-mortal samples was less pronounced. Specimens of 3 HIV- and 2 HBV-infected patients taken 24 h post mortem or later were even found to have increased concentrations (>10-fold), possibly due to post-mortem liberation of virus from particular cells or tissues. Conclusion: Our preliminary data indicate that the time point of blood collection for HIV, HBV and HCV testing by PCR may be extended to 36 h or even 48 h post mortem and thus improve availability of tissue donations.

[1]  S. Polywka,et al.  A prospective time-course study on serological testing for human immunodeficiency virus, hepatitis B virus and hepatitis C virus with blood samples taken up to 48 h after death. , 2011, Journal of medical microbiology.

[2]  L. Kucirka,et al.  Risk of Window Period Hepatitis‐C Infection in High Infectious Risk Donors: Systematic Review and Meta‐Analysis , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  L. Kucirka,et al.  High infectious risk donors: what are the risks and when are they too high? , 2011, Current opinion in organ transplantation.

[4]  K. Ellingsona,et al.  Estimated Risk of Human Immunodeficiency Virus and Hepatitis C Virus Infection among Potential Organ Donors from 17 Organ Procurement Organizations in the United States , 2011 .

[5]  D. Krüger,et al.  Tissue donation and virus safety: more nucleic acid amplification testing is needed , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  Michael P Busch,et al.  Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus , 2008, Transfusion.

[7]  R. Seitz,et al.  Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools , 2008, Transfusion.

[8]  J. Pawlotsky,et al.  Serological Viral Testing of Cadaveric Cornea Donors , 2006, Transplantation.

[9]  S. Kleinman,et al.  Assessing the impact of HBV NAT on window period reduction and residual risk. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  P. Patel,et al.  Transmission of Hepatitis C Virus to Several Organ and Tissue Recipients from an Antibody-Negative Donor , 2005, Annals of Internal Medicine.

[11]  S. Glynn,et al.  A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors , 2005, Transfusion.

[12]  J. Trotter Transmission of hepatitis C by implantation of a processed bone graft. A case report. , 2003, The Journal of bone and joint surgery. American volume.

[13]  L. Rostaing,et al.  Screening of blood from potential organ and cornea donors for viruses , 2002, Journal of medical virology.

[14]  S. Kleinman,et al.  Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases , 2000 .

[15]  S. Kleinman,et al.  Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. , 2000, Transfusion.

[16]  A. Heim,et al.  Evaluation of serological screening of cadaveric sera for donor selection for cornea transplantation , 1999, Journal of medical virology.

[17]  W. Köhler MiQ: Qualitatsstandards in der mikrobiologisch-infektiologischen Diagnostik. Gustav Fischer Verlag, Villanova Pa. (1997), Ringordner, DM 98.- , 1998 .

[18]  C. Delloye,et al.  Polymerase chain reaction in cadaveric blood and tissues. , 1996, Transplantation proceedings.

[19]  J. Pepose,et al.  New developments in serologic screening of corneal donors for HIV-1 and hepatitis B virus infections. , 1992, Ophthalmology.

[20]  S. Holmberg,et al.  Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. , 1992, The New England journal of medicine.